FindTrial
Sign In

CV301

BIOLOGICAL4 trials

Sponsors

Bavarian Nordic, Georgetown University, National Cancer Institute (NCI)

Conditions

Bladder CancerColorectal AdenocarcinomaColorectal CancersMetastatic Colorectal CancerMetastatic Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Pancreatic AdenocarcinomaSmall Bowel Cancers

Phase 1

A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
CompletedNCT02840994
Bavarian NordicNon-small Cell Lung Cancer (NSCLC)
Start: 2016-12-31End: 2020-01-31Updated: 2020-02-27
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
TerminatedNCT03376659
Georgetown UniversityColorectal Adenocarcinoma, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer +1
Start: 2018-08-08End: 2023-08-01Updated: 2024-02-05

Phase 2

CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
CompletedNCT03628716
Bavarian NordicBladder Cancer
Start: 2018-09-18End: 2021-02-02Updated: 2022-04-27
Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers
CompletedNCT04491955
National Cancer Institute (NCI)Colorectal Cancers, Small Bowel Cancers
Start: 2020-09-22End: 2024-08-16Updated: 2025-04-24

Related Papers

The Quadruple Immunotherapy for Colorectal Cancer (QuICC) Trial for Mismatch Repair-Proficient Metastatic Colorectal Cancer.
2026-01-10
New advances in cancer therapy targeting TGF-β signaling pathways
Molecular Therapy — Oncolytics2023-12-0127 citations
Phase II evaluation of combination immunotherapy with CV301, N-803, bintrafusp alfa, and M9241 in patients with advanced small bowel and colorectal cancers.
Journal of Clinical Oncology2023-01-243 citations
Phase 1 trial of <scp>CV301</scp> in combination with <scp>anti‐PD</scp>‐1 therapy in <scp>nonsquamous non‐small</scp> cell lung cancer
International Journal of Cancer2022-08-2710 citations
Phase 2 trial of CV301 vaccine plus atezolizumab (Atezo) in advanced urothelial carcinoma (aUC).
Journal of Clinical Oncology2022-02-162 citations
A phase II, multicenter, single-arm trial of CV301 plus atezolizumab (Atezo) in locally advanced (unresectable) or metastatic urothelial cancer (UC).
Journal of Clinical Oncology2019-03-01
A trial of CV301 in combination with anti-PD-1 therapy versus anti-PD-1 therapy in subjects with non-small cell lung cancer.
Journal of Clinical Oncology2018-05-202 citations